TP53 has been shown to regulate a multitude of metabolic pathways in solid tumors, including glucose metabolism, oxidative phosphorylation, lipid metabolism, nucleotide metabolism etc. (80), but very little is known on its potential role in metabolic regulation in AML and further work is needed to elucidate if metabolic targeting could result in novel therapeutic strategies for AML patients harboring TP53 mutations. Here, TP53 is linked to acute myeloid leukemia.